Introduction {#sec1-1}
============

Chemotherapy remains a common treatment modality of cancer. Irrespective of the fact that chemotherapy expands survival, this often leads to the most debilitating and distressing side effects in the form of nausea and vomiting. Distinct obstacle to the furtherance of chemotherapy is the failure to prevent chemotherapy-induced nausea and vomiting (CINV) completely which may result in down gradation of the physical and mental status of the patient while leading to poor compliance rate for the next cycle of chemotherapy. Therefore, avoidance or alleviation of CINV is of utmost importance for better patient outcomes to chemotherapy.\[[@ref1][@ref2][@ref3]\]

The incidence of CINV varies from 30% to \>90% within the first 24 h of introducing moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) regimen without antiemetic prophylaxis. Preventing CINV from the initiation of chemotherapy is important because effective control in the acute phase (AP) (0--24 h after chemotherapy) is linked with decreased incidence of CINV in the delayed phase (DP) (day 2 onward).\[[@ref4]\] Similarly, control in the first cycle is linked with decreased incidence in subsequent cycles with few patients developing anticipatory nausea and vomiting in later cycles.\[[@ref5][@ref6]\]

Various clinical studies suggest the incidence of 28--50% for Delayed emesis in patients receiving HEC/MEC regimens.\[[@ref7][@ref8]\] In AP 5-HT3 receptor thought to be is the main causative agent, which is well controlled with 5-HT3 RA and dexamethasone. In the contrary to this DP is under the control of substance *P* and neurokinin-1 (NK-1) receptor system. Two drug therapies without the aprepitant has not demonstrated good control in DP with improbable maintenance of antiemetic efficacy, especially over repeated administration of HEC regimens. Triple therapy with aprepitant improves complete response (CR) rate in DP. Clinicians are likely to underestimate DP CINV which is more frequent than the AP and patient who did not have suffered AP is likely to suffer DP CINV.\[[@ref5][@ref9]\] Moreover, negative effects on quality of life (QoL) are more with DP CINV rather than AP CINV indicating addition of aprepitant to prevent DP CINV would benefit patients receiving chemotherapy.\[[@ref6][@ref10][@ref11]\]

There are limited data available for use of aprepitant in Indian patients and therefore the current study was conducted to evaluate the efficacy and safety of this triple regimen containing the same on CINV related outcomes when administered to patients receiving HEC/MEC drug regimens for various cancers in the first cycle.

Subjects and Methods {#sec1-2}
====================

An investigator-initiated, multicentric, noncomparative, prospective observational study was conducted at different oncology centers of Maharashtra in India. The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice with study approval from an Independent Ethics Committee and written informed consent from the patients.

Inclusion criteria {#sec2-1}
------------------

Seventy-five male or female patients from Oncology department with age ≥ 18 years, with various malignancies including breast (*n* = 29), colorectal (*n* = 5), gastrointestinal (*n* = 7), gynecological (*n* = 13), head and neck (*n* = 9), hematological (*n* = 6), lung (*n* = 4), bone (*n* = 2), who had an Eastern Cooperative Oncology Group Performance Status of 0--2 and likely to undergo 4--6 cycles of HEC or MEC drugs or regimens were enrolled in the study. The emetogenicity of the chemotherapy was defined as HEC or MEC as per National Comprehensive Cancer Network (NCCN) guidelines, 2013.

Exclusion criteria {#sec2-2}
------------------

Main exclusion criteria included: Emesis within prior 24 h of starting chemotherapy; symptomatic primary brain tumor or metastasis in the brain; previous radiation to the brain, abdomen or pelvis, any active infection or uncontrolled disease; and any systemic steroid therapy.

Medication and dosage {#sec2-3}
---------------------

All eligible patients received aprepitant p.o. 125 mg (day 1), 80 mg (day 2--3) along with intravenous (IV) palonosetron injection 0.25 mg (day 1) and dexamethasone IV injection and p.o. on day 1 and subsequent days.

Patients recorded any episodes of nausea and/or vomiting episodes and their use of rescue medication a (dopamine antagonist) in a diary during the first 120 h after initiation of chemotherapy. Based on patient observations, the investigator assessed the severity of CINV according to a four-point Likert scale (any, mild, moderate or severe nausea). A vomiting episode was defined as one or more distinct episodes of emesis (expulsion of stomach contents through the mouth) or retches (an attempt to vomit that is not productive of stomach contents).

Endpoints {#sec2-4}
---------

The primary efficacy endpoint was CR defined as no emetic episodes and no use of any rescue therapy during the 5 days (120 h) following the initiation of chemotherapy. The key secondary efficacy endpoint was complete control (CC) defined as no emesis, no rescue medication and no more than mild nausea during the 5 days (120 h) following initiation of chemotherapy. The AP response was recorded on day 1 (0--24 h) of chemotherapy and DP from day 2 to 5 (25--120 h), while overall phase (OP) response being calculated from day 1 to 5.

Evaluation of safety {#sec2-5}
--------------------

Adverse events and laboratory data were compiled according to the Common Terminology Criteria for Adverse Events (version 4).

Statistics {#sec2-6}
----------

According to the protocol-defined exclusion criteria, the perprotocol efficacy was analyzed for the first cycle with results represented in terms of CR/CC rates. Similarly, the concomitant risk factors, including baseline patient demographics such as age and sex, past history a primary cancer site and HEC/MEC drug administered were also assessed. Data were analyzed by descriptive statistics.

Results {#sec1-3}
=======

Patient characteristics and treatment {#sec2-7}
-------------------------------------

Seventy-five outpatients who completed at least four cycles of chemotherapy for various malignancies including breast cancer (*n* = 29), colorectal (*n* = 5), gastrointestinal tract (*n* = 7), gynecological (*n* = 13), head and neck (*n* = 9), hematological (*n* = 6), lung (*n* = 4) and bone (*n* = 2) were included for analysis with results represented for the first cycle. Overall, 89.7% of patients were females, and the mean age was 49.7 years. Nineteen patients (26.3%) had concomitant comorbid condition including hypertension, type 2 diabetes or COPD. The demographic data is mentioned in [Table 1](#T1){ref-type="table"}.

###### 

Baseline demographics for the patients enrolled in the study

![](SAJC-4-7-g001)

Chemotherapy drugs were grouped as per their emetogenicity into HEC and MEC. 60% of patients received HEC drugs, and rest received MEC drugs. The most common HEC drugs were an anthracycline plus cyclophosphamide and cisplatin ≥ 50 mg/m^2^. The most commonly used HEC and MEC drugs included anthracycline plus cyclophosphamide and carboplatin respectively. Polovinch *et al*. (2009) reclassified the emetogenicity of MEC drugs as HEC regimen when used in combination. The HEC regimens, therefore, included AC, Cisplatin-Docetaxel, Cisplatin-Paclitaxel, ABVD, FEC, EOF, FOLFIRI. These consisted of 85.3% of all the regimens being administered.

Antiemetic efficacy {#sec2-8}
-------------------

The occurrence of nausea and vomiting was evaluated using patient questionnaires. The CR and CC rates were compared among all, MEC and HEC regimens used during the study \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\]. The CR rates for overall, acute, DP were 96.8%, 93.7% and 92% respectively for patients receiving HEC regimen.

![Comparison of complete response for highly emetogenic chemotherapy, moderately emetogenic chemotherapy and all regimens](SAJC-4-7-g002){#F1}

![Comparison of complete control for highly emetogenic chemotherapy, moderately emetogenic chemotherapy and all regimens](SAJC-4-7-g003){#F2}

Similarly the CC rates for overall, acute, DP were 75%, 85.4% and 75% respectively for HEC regimen. Five cases of persistent CIN or CINV were noted. Two of these cases were labeled as Grade 3 and 4 severities that were managed with rescue medication involving injection metoclopramide.

Safety {#sec2-9}
------

Overall 7 (9.2%) patients experienced adverse reactions which were mild and well tolerated. The most common side-effect observed was hiccough in 2 (2.7%). Other adverse drug reactions observed included mucositis (1.3%), dysphagia (1.3%), generalized weakness (1.3%), constipation (1.3%) and body pain (1.3%). No Grade 3 or 4 adverse events were reported during the study.

Risk analysis {#sec2-10}
-------------

For the five cases with persistent CIN or CINV, categorical or continuous variable risk factor analyses were performed. Most of these cases may be influenced by gender status (females) with Age ≤ 40 years (50%) for not achieving CR with the administered prophylactic regime. Rescue antiemetic treatment was administered in alone case.

Discussion {#sec1-4}
==========

In this prospective observational multicenter CINV prophylaxis study in Indian patients with various malignancies, triple therapy with aprepitant (an NK-1 receptor antagonist), palonosetron (a second generation 5 HT3 receptor antagonist), and dexamethasone was associated with high CR and CC rates over 5 days of cycle 1 of HEC or MEC administered.\[[@ref3][@ref4][@ref14][@ref15]\]

There is scarce data available about the risk of CINV and the efficacy of antiemetic Regimens in Indian or Asian patients involving HEC and/or MEC regimens.

Most CINV prophylaxis studies with effect on the QoL are characterized by narrow patient selection criteria and are limited to well-defined chemotherapy regimens of different levels of emetogenicity with less due representation to local geographic population.\[[@ref10][@ref16]\]

Several researchers have demonstrated that Aprepitant-containing antiemetic regimen for patients with a variety of cancer types treated with MEC has shown greater efficacy than the control regimen. As a result, a three-drug regimen including 5HT3-receptor antagonist, dexamethasone, and aprepitant has been incorporated into the Multinational Association of Supportive Care in Cancer, European Society for Medical Oncology, American Society of Clinical Oncology and the NCCN guidelines for prevention of CINV in patients receiving selected MEC regimens. This strategy is especially relevant for select patients receiving certain moderate emetic risk chemotherapy (i.e. carboplatin, cisplatin, doxorubicin, epirubicin, ifosfamide, irinotecan or methotrexate).\[[@ref17]\]

The results of our study are consistent with those from previous similar studies of CINV prophylaxis for patients receiving HEC \[[Table 2](#T2){ref-type="table"}\] or MEC regimens.\[[@ref5]\]

###### 

Comparison of CR rates from various studies receiving triple regimen with aprepitant

![](SAJC-4-7-g004)

In this study, the prophylaxis regimen resulted in CR of 92.6% for OP in patients receiving HEC based regimens with similar rates of "No emesis." Maru *et al*. showed CR of 73.4% that was again similar in the "No emesis" group and probably related to the single day administration of ondansetron.

Five of the enrolled patients showed in CR to the prophylaxis therapy with one showing grade 3 severity as per NCI-Toxicity criteria and was well controlled with rescue medication.

The CR rates in the current study (90%) for patients treated with MEC Regimens was comparable to study results from Ito *et al*.\[[@ref5]\] (80.3%) and Ryu *et al*. (96.3%).\[[@ref17]\]

Chemotherapy cycles administered repeatedly may lead to CINV that becomes progressively more difficult to control. The efficacy of antiemetic prophylaxis is, therefore, evaluated during the first chemotherapy cycle as it is known that pretreated patients are at a higher risk of emesis and anticipatory vomiting in the following cycles.\[[@ref18]\]

In the current study, supplementation of antiemesis regimen with aprepitant was well tolerated with mild AEs including hiccough (2.7%) being reported. The reported incidence of hiccough was again comparable to other studies including Jordan *et al*.\[[@ref9]\] Other AEs noted were mucositis, dysphagia, generalized weakness, constipation and body pain where the causality could not be confirmed with the use of aprepitant.

Overall the safety experience in the Indian population was similar to the reported incidence for aprepitant in published literature.

In the current study, the incidence of Nausea reported by patients (34.7%) was comparable to results from Longo *et al*., (38.5%). The relative high incidence of Nausea in both the studies could be partly related to the lack of conformity for NCCN guidelines (2013) where steroids are recommended for 4 days, especially for HEC regimens.\[[@ref19]\] This may be attributable to the relative persistence of Nausea (moderate intensity) in 5 (7.8%) patients on day 4 and 5 for the CINV prophylaxis regimen administered group.

The study was limited by small sample size which narrates further need of a large randomized study trial with the standardized dosage schedule of NK-1-RA (3 days), 5-HT3-RA (day 1) and dexamethasone (4 days) by NCCN recommendations (2013) to confirm the benefits of such treatment strategies especially for HEC drug combination Regimens.

Conclusion {#sec1-5}
==========

The study confirms the clinical benefits of aprepitant supplementation in patients receiving HEC/MEC Regimens for various malignancies along with 5-HT3 antagonist and steroids, thereby offering improved prevention of CINV. The combination is well-tolerated with no augmentation of any adverse drug-drug interaction with most of the commonly co-prescribed medications in patients receiving chemotherapy.
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